Masimo Corp Stock Price, News & Analysis

Masimo (Nasdaq: MASI) reported strong Q2 2025 financial results, with GAAP revenue reaching $371 million, up 8% year-over-year. The company achieved non-GAAP earnings per diluted share of $1.33, representing a 46% increase from the previous year.

CEO Katie Szyman highlighted the company's successful tariff mitigation efforts, reducing the expected impact by 50%. For 2025, Masimo updated its guidance to include non-GAAP revenue of $1,505-$1,535 million, projecting 8-11% growth. The company revised its non-GAAP EPS guidance to $5.20-$5.45 including tariff impacts, down from $5.45-$5.70 before tariffs.

Masimo (NASDAQ: MASI) has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, after market close. The company will host a conference call at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results for the period ended June 28, 2025.

The conference call will be led by CEO Katie Szyman and CFO Micah Young. Participants must register in advance to receive dial-in details and a registrant ID. A replay of the webcast and conference call will be available on Masimo's website after the event.

Masimo (NASDAQ: MASI), a medical technology company specializing in noninvasive monitoring solutions, has joined the American Heart Association Center for Health Technology & Innovation's Innovators' Network. This strategic collaboration provides Masimo access to the Association's digital evidence-based guidelines and clinical recommendations for healthcare technology development.

The Innovators' Network connects entrepreneurs, providers, researchers, and payers, facilitating the development of clinical outcome studies and evidence-based healthcare technologies. Members can leverage the consortium to validate that their digital platforms improve healthcare outcomes, a crucial factor for providers and payers.

A clinical trial published in JAMA Pediatrics demonstrates significant benefits of Masimo SedLine Brain Function Monitoring in pediatric anesthesia. The study showed that EEG-guided anesthesia using SedLine reduced sevoflurane exposure by 1.4 MAC hours and decreased pediatric anesthesia emergence delirium (PAED) incidence by 14%. Patients monitored with SedLine regained consciousness 53% faster and were discharged from post-anesthesia care 48% sooner, resulting in cost savings of $240-$920 per patient. The randomized trial, conducted at Japan's largest children's hospital, involved 177 children aged 1-6 years undergoing elective surgery. The technology demonstrated improved safety, efficiency, and cost-effectiveness in pediatric anesthesia management compared to standard practice.

Masimo (NASDAQ: MASI) has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management will present on Wednesday, June 4, 2025, at 1:25 p.m. Eastern time. Investors and interested parties can access a live webcast of the presentation through Masimo's website. Additionally, a replay of the webcast will be made available after the live presentation.

Masimo (NASDAQ: MASI) has announced its participation in the upcoming BofA Securities 2025 Health Care Conference. The company's management will present on Tuesday, May 13, 2025, at 4:20 p.m. Pacific time. Investors and interested parties can access a live webcast of the presentation through Masimo's website. Additionally, a replay of the webcast will be made available after the live presentation concludes.

Masimo (NASDAQ: MASI) has announced the sale of its Sound United consumer audio business to HARMAN International, a Samsung Electronics subsidiary, for $350 million in cash. The transaction, expected to close by the end of 2025, aligns with Masimo's strategic focus on its core professional healthcare segment.

The deal will integrate Sound United's premium audio brands, including Bowers & Wilkins, Denon, and Marantz, into HARMAN's existing portfolio of JBL, Harman Kardon, and other brands. This strategic move, led by CEO Katie Szyman, aims to streamline Masimo's operations and redirect resources toward addressing unmet clinical needs while driving growth and operational efficiencies.

Masimo (MASI) reported strong Q1 2025 financial results with GAAP revenue of $372 million, up 10% year-over-year. The company achieved non-GAAP earnings per diluted share of $1.36, representing a 56% growth compared to the previous year. However, the company reported a $218 million loss from discontinued operations, including a $295 million impairment of intangibles for its non-healthcare consumer business. New CEO Katie Szyman expressed confidence in Masimo's technology advantage and team strength. For 2025, Masimo updated its guidance to include the impact of new tariffs, projecting non-GAAP revenue of $1.5-1.53 billion (8-11% growth) and non-GAAP earnings per diluted share of $4.80-$5.15, down from the previous $5.30-$5.60 range due to tariff impacts. The company is developing mitigation plans to address tariff challenges through adjusted product sourcing and operations.

Masimo (NASDAQ: MASI) has scheduled its first quarter 2025 financial results announcement for Tuesday, May 6, 2025, after market close. The results will cover the period ended March 29, 2025.

The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to review the results, led by CEO Katie Szyman and CFO Micah Young. Participants must register online to receive dial-in details and a registrant ID. A replay will be available after the call and archived on Masimo's website.